Hansa Medical's 'Game Changer' In Transplantations May Have Other Uses Too
Executive Summary
Hansa Medical AB, a Swedish-listed, clinical-stage biotech, is focused on developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases that could change the face of kidney transplants.
You may also be interested in...
Data Raise Hopes Of Accelerated Approval For Hansa's Kidney Transplant-Enabling Imlifidase
Kidney transplantation might be possible in difficult-to-graft highly sensitized patients using Hansa Medical's IgG-cleaving product, imlifidase. The high unmet need for such a product might usher in a Phase II data-based approval.
Hansa Medical CEO Arvidson Dies
Hansa Medical announces the sudden death of its CEO Göran Arvidson.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.